Cooperative sites enhance clinical insights in sickle cell disease, indicating improved research priorities.
Historically, Sickle Cell Disease (SCD) has been overshadowed by progress in other hematologic disorders, but recent advances are reshaping its clinical and research landscape. Despite SCD reducing life expectancy by more than 20 years even with optimal care, transformative initiatives are fostering hope for improved outcomes. The American Society of Hematology (ASH) established the ASH Research Collaborative Sickle Cell Disease Research Network as a comprehensive program to revolutionize SCD research in the United States. This Network comprises a collection of innovative, research-focused cooperative sites and a robust Data Hub that aggregates extensive real-world datasets to enhance clinical insights and streamline research designs. Community Advisory Boards at both local and national levels ensure that the perspectives of individuals living with SCD guide research priorities. This report includes an overview of the initial demographics, including the number of records, encounters, laboratory data, prescriptions, years of follow-up, and co-morbidities per patient, within the context of the ASH Research Collaborative Sickle Cell Disease Research Network. These coordinated efforts are poised to significantly transform the landscape of SCD care, and this report details the initiative's mission, history, achievements to date, and its promising trajectory toward improving the lives of individuals affected by this chronic condition.
No takes yet. Share an insight, caveat, or question.
Rassi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: